Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Centre Oscar Lambret

Status: Unknown

Conditions: Epidermoid Head and Neck Cancer

Treatments: Drug: Cetuximab; Radiation: Radiotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT01647555

ESPACE

Details and patient eligibility

About

This study evaluates the skin toxicities in patients with epidermoid cancer, treated by Radiotherapy in association with Cetuximab.

Enrollment: 57 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years
• Epidermoid head and neck carcinoma locally advanced
• Indication of Cetuximab and radiotherapy
• Karnofsky >= 60
• Patients participating to another compatible study could be included after consultation with the study director Patients could be beforehand treated for an other ORL cancer

The radiotherapy will be delivered for curative aim (minimal dose 66 Gy)

Exclusion criteria

• other histology
• Metastatic disease
• Recurrent patients

Trial design

57 participants in 1 patient group

patient with epidermoid cancer

Description:

receiving Cetuximab and radiotherapy

Treatment:

Radiation: Radiotherapy

Drug: Cetuximab